Glenmark to begin Phase 3 clinical trials on Favipiravir

The Mumbai-based company Glenmark Pharmaceuticals said that it has initiated Phase 3 clinical trials on antiviral drug Favipiravir to check its effectiveness on COVID-19 patients in India. Last month, The company received approval from Drug Controller General of India (DCGI) to conduct clinical trials of Favipiravir antiviral tablets for the treatment of deadly corona virus.

By initiating the Phase 3 clinical trials on Favipiravir, Glenmark Pharmaceuticals has become the first in India to conduct trial for COVID-19 patients, it said in a statement. Over ten leading government and private hospitals are being enrolled for the study, company further added. Glenmark estimates study completion by July or August 2020.

150 subjects with mild to moderate COVID-19 symptoms will be randomised in the study in a 1:1 ratio to Favipiravir with standard supportive care or standalone standard supportive care. The duration of the treatment is a maximum of 14 days and the total study duration will be a maximum of 28 days from randomisation, as per the approved clinical trial protocol.

Glenmark Pharmaceuticals Vice President & Head Clinical Development, Global Specialty/Branded Portfolio Monika Tandon said, “Several health and medical experts, both in and outside of Glenmark are eager to see the effect that Favipiravir has on COVID-19 cases. We believe the study results will be significant as there is currently no effective treatment for the virus. The data we get from these trials will point us in a clearer direction with regard to COVID-19 treatment and management.”

The company’s main object is to launch a treatment for COVID-19 patients so as to stop spread of the pandemic, according to Glenmark.

  • Related Posts

    • Pharma
    • July 24, 2025
    • 76 views
    Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

    Natco Pharma shares slipped 2.5% to Rs 1,009 apiece on the BSE in Thursday’s trade after the company announced its plan to acquire a 35.75% stake in South Africa-based Adcock…

    • Pharma
    • July 22, 2025
    • 173 views
    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    The Directorate General of Foreign Trade ( DGFT ) has notified an extension in the deadline for submitting applications for the export of Pharma Grade Sugar. This was communicated through Trade Notice…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

    Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

    10, 000 Km is just a Number for Intercontinental Tele Surgery by SSIMantra

    10, 000 Km is just a Number for Intercontinental Tele Surgery by SSIMantra

    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra

    Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra